

Time	Program Number	Title and Authors
7:00 am	43	<b>Development of a VA Protocol for Buprenorphine Use Perioperatively for Elective and Emergency Procedures</b>  Jeffrey Fudin <sup>1</sup> , Nayma Moya Romero <sup>2</sup> , Jeffrey Bettinger <sup>1</sup> , Abigail Brooks <sup>2</sup> , Sandra DiScala <sup>2</sup> , Christine Vartan <sup>2</sup> <sup>1</sup> Stratton Veteran Affairs Medical Center, Albany, New York, USA. <sup>2</sup> West Palm Beach Veteran Affairs Medical Center, West Palm Beach, Florida, USA
7:08 am	80	<b>Efficacy and Safety of Lofexidine for Opioid Withdrawal Syndrome: Pooled Analysis of Phase 3 Studies</b>  Mark Pirner <sup>1</sup> , Carlos Tirado <sup>2</sup> , Thomas Clinch <sup>1</sup> <sup>1</sup> US WorldMeds, Louisville, Kentucky, USA. <sup>2</sup> CARMAhealth, LLC, Austin, Texas, USA
7:16 am	83	<b>Botulinum Toxin Type A for Neuropathic Pain in Patients with Spinal Cord Injury</b>  Myungeun Chung The Catholic University of Korea, Seoul, Republic of South Korea
7:24 am	91	<b>Indirect-Acting Strategy of Opioid Action Rather Than Direct Receptor Activation: Dual-Acting Enkephalinase Inhibitors (DENKIs)</b>  Robert Raffa <sup>1,2,3</sup> , Joseph Pergolizzi <sup>3,4</sup> , Robert Taylor <sup>4</sup> , Michael Ossipov <sup>5</sup> <sup>1</sup> University of Arizona College of Pharmacy, Tucson, AZ, USA. <sup>2</sup> Temple University School of Pharmacy, Philadelphia, PA, USA. <sup>3</sup> Neumentum Inc, Palo Alto, CA, USA. <sup>4</sup> NEMA Research Inc, Naples, FL, USA. <sup>5</sup> University of Arizona College of Medicine, Tucson, AZ, USA
7:32 am	99	<b>Effect of Baseline Characteristics on Outcomes of Oral Methylnaltrexone for Opioid-Induced Constipation</b>  Richard Rauck <sup>1</sup> , Neal E. Slatkin <sup>2,3</sup> , Nancy Stambler <sup>4</sup> , Robert J. Israel <sup>3</sup> <sup>1</sup> Carolinas Pain Institute, Winston-Salem, NC, USA. <sup>2</sup> University of California Riverside, School of Medicine, Riverside, CA, USA. <sup>3</sup> Salix Pharmaceuticals, Bridgewater, NJ, USA. <sup>4</sup> Progenics Pharmaceuticals, Inc., New York, NY, USA
7:40 am	108	<b>Persistence of Effect of Galcanezumab in Patients with Episodic or Chronic Migraine: Phase3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2 and REGAIN Studies</b>  Sheena K. Aurora, Qi Zhang, Virginia L. Stauffer, Marissa I. Daniele Eli Lilly and Company, Indianapolis, IN, USA